Tuberculosis, Multidrug-Resistant: all 132 studies
Page 2 of 2. Open to participants first (25), then studies with results posted, then the rest; newest registration first within each.
- Drug Concentrations in the Treatment of MDR-TB Related to Minimum Inhibitory ConcentrationsCompletedNCT02816931
- Pharmacokinetic and Therapeutic Adaptation of Linezolid in the Treatment of Multi-Resistant TuberculosisCompletedNCT02778828Not applicable
- Evaluating Newly Approved Drugs for Multidrug-resistant TBCompletedNCT02754765Phase 3
- Pharmacometric Optimization of Second Line Drugs for MDR Tuberculosis TreatmentCompletedNCT02727582
- Study of TB Lesions Obtained in Therapeutical SurgeryCompletedNCT02715271
- Safety of RUTI® Vaccination in MDR-TB PatientsTerminatedNCT02711735Phase 2
- FS-1 Drug for Treatment of Multiple Drug-resistant TuberculosisCompletedNCT02607449Phase 3
- Biomarkers for Therapy Response in Drug-resistant TuberculosisCompletedNCT02597621
- Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s)CompletedNCT02589782Phase 2/3
- Effectiveness of a Simplified Short Regimen for Multidrug Resistant Tuberculosis in UzbekistanStatus unknownNCT02496572
- An Open-label RCT to Evaluate a New Treatment Regimen for Patients With Multi-drug Resistant TuberculosisCompletedNCT02454205Phase 2/3
- Nosocomial Transmission of MDR-TB in Bucharest, RomaniaCompletedNCT02413931
- An Exploratory Study of TMC207 in Japanese Participants With Pulmonary Multi-Drug Resistant Tuberculosis (MDR-TB)CompletedNCT02365623Phase 2
- Pharmacokinetic Study to Evaluate Anti-mycobacterial Activity of TMC207 in Combination With Background Regimen (BR) of Multidrug Resistant Tuberculosis (MDR-TB) Medications for Treatment of Children/Adolescents With Pulmonary MDR-TBSuspendedNCT02354014Phase 2
- A Prospective Patient Registry of Patients Exposed to BedaquilineCompletedNCT02274389
- Genome Sequencing of Multidrug Resistant Tuberculosis (MDR TB) in SputumStatus unknownNCT02245347
- Brief Bactericidal Activity of Anti-Tuberculosis DrugsCompletedNCT02236078Phase 1
- Rewards for Tuberculosis Contact ScreeningCompletedNCT02234908Not applicable
- Intensifying Multi-Drug Resistant Tuberculosis Contact Tracing by Social Network AnalysisCompletedNCT02175849
- Global Consortium for Drug-resistant Tuberculosis DiagnosticsCompletedNCT02170441
- Pharmacokinetics of Levofloxacin and Capreomycin in Multidrug-Resistant Tuberculosis PatientsCompletedNCT02169141
- Optimization of MDR-TB Treatment Regimen Based on the Molecular Drug Susceptibility Results of PyrazinamideStatus unknownNCT02120638Phase 3
- TB Immunotherapy Trial With Heat-killed M. VaccaeCompletedNCT01977768Phase 3
- Pharmacokinetic and Safety Trial to Determine the Appropriate Dose for Pediatric Patients With Multidrug Resistant TuberculosisCompletedNCT01856634Phase 1
- A Study to Evaluate the Efficacy and Safety of TMC207 in Patients With Pulmonary Infection With Multi-drug Resistant Mycobacterium TuberculosisWithdrawnNCT01600963Phase 3
- Safety and Efficacy of Oral Immunomodulator in Tuberculosis (TB) and TB/HIV PatientsCompletedNCT01222338Phase 2
- Operational Assessment of Laboratory Information System for MDR-TB in Lima, PeruCompletedNCT01201941
- Tuberculosis in ChinaCompletedNCT01071603
- Adjunct Immunotherapy With Immunoxel in Patients With TB and TB/HIVCompletedNCT01061593Phase 3
- Comparison of the Effect Between Levofloxacin and Moxifloxacin Among MDR-TB PatientsTerminatedNCT01055145Phase 3
- Epidemiology of MDR-TB in PeruStatus unknownNCT00676754
- High-Dose Isoniazid Adjuvant Therapy for Multidrug Resistant TuberculosisCompletedNCT00513396Phase 2/3